Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-ALA plus Gliadel wafers in surgery for primary glioblastoma
ISRCTN77105850Phase 2Completed
- Sponsor
- University College London
- Start
- May 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of 5-aminolevulinic acid and carmustine in glioblastoma (GBM), sponsored by University College London. Primary endpoints: Percentage of 5-ALA resected patients receiving Carmustine wafers, Postoperative complication rate and 4 more. Started May 2011; status: completed.
02
Drugs
5-aminolevulinic acidcarmustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ISRCTN77105850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN77105850.